Results 11 to 20 of about 8,815 (184)

DCB combined with provisional DES implantation in the treatment of De Novo Medina 0,1,0 or 0,0,1 left main coronary bifurcation lesions: A proof-of-concept study

Anatolian Journal of Cardiology, 2022
Objective: To investigate the safety and efficacy of a percutaneous revascularization strategy that is based on the use of drug-coated balloon for the treatment of patients with acute coronary syndrome and de novo Medina type 0,1,0 or 0,0,1 left main ...
Emrah Erdoğan, Zheng Li, Yong-xiang Zhu, Vincenzo Tufaro, Si-li Feng, Qian Li, Li Liang, Shang Chang, Ling-tong Bu, Bing Liu, Qi-hua Zhou, Nathan A. L. Yap, Christos V. Bourantas, Yao-jun Zhang   +13 more
doaj   +1 more source

Safety and Efficacy of an Innovative Everolimus-Coated Balloon in a Swine Coronary Artery Model

Life, 2023
Background: Drug-coated balloons have been used as a non-stenting treatment in coronary and peripheral artery disease. Until recently, only sirolimus- and paclitaxel-coated balloons have been investigated in clinical trials.
Christos S. Katsouras, Alexandros Tousis, Georgios Vasilagkos, Arsen Semertzioglou, Athanassios Vratimos, Ioanna Samara, Georgia Karanasiou, Vasileios S. Loukas, Grigorios Tsigkas, Dimitrios Fotiadis, Lampros K. Michalis, Periklis Davlouros, Anargyros N. Moulas   +12 more
doaj   +1 more source

Drug-Coated Balloon After Intravascular Lithotripsy: Procedural and Clinical Outcome of the "Crack and Drug" Strategy. [PDF]

JACC Adv
Oliveri F, van Oort MJH, Phagu AAS, Al Amri I, Bingen BO, Paradies V, Mincione G, Claessen BEPM, Dimitriu-Leen AC, Kefer J, Girgis H, Vossenberg T, Mandurino-Mirizzi A, Van der Kley F, Jukema JW, Montero-Cabezas J.   +15 more
europepmc   +2 more sources

Temporal reverse flow by proximal femoral artery occlusion during drug-coated balloon dilatation: a technique to minimize downstream particle embolization and systemic adverse effects

Journal of Vascular Surgery Cases and Innovative Techniques, 2021
Downstream paclitaxel particle embolization for nonhealing ischemic ulcers and systemic adverse effects caused by a paclitaxel drug-coated balloon are of concern, and safety measures to prevent these adverse risks are needed.
Masayoshi Kimura, MD, Jun Shiraishi, MD, PhD, Masayuki Hyogo, MD, Takahisa Sawada, MD, PhD   +3 more
doaj   +1 more source

Technical success, clinical efficacy, and insight into the causes of restenosis after the percutaneous coronary intervention of de novo coronary artery lesions using a paclitaxel-coated balloon with citrate ester excipient

Frontiers in Cardiovascular Medicine, 2022
ObjectivesThe aim of this all-comers registry study was to investigate the technical success, clinical efficacy, and safety of a drug-coated balloon (DCB) with paclitaxel combined with citrate ester excipient (CEE) in percutaneous coronary intervention ...
Jerry Tervo, Jussi M. Kärkkäinen, Tuomas T. Rissanen   +2 more
doaj   +1 more source

Effect of High-Dose Drug-Coated Balloon Repetition After Drug-Coated Balloon Failure

Journal of Endovascular Therapy, 2023
Purpose: Although the optimal treatment for femoropopliteal (FP) drug-coated balloon (DCB) restenosis lesions remains debatable, the effectiveness of DCB repetition for DCB restenosis has been reported. However, the optimal DCB repetition strategy is not yet established.
Yusuke Tomoi, Mitsuyoshi Takahara, Yoshimitsu Soga, Taichi Hirano, Kazuki Tsunoda, Tomonori Katsuki, Kenji Ando   +6 more
openaire   +2 more sources

Twisting of the Ranger drug‐coated balloon for treating superficial femoral artery disease

Clinical Case Reports, 2022
Paclitaxel‐coated balloons have demonstrated improved efficacy compared with uncoated percutaneous transluminal angioplasty for femoropopliteal artery disease. While applying a long balloon, twisting of the balloon can be occurred.
Su Hong Kim, Jong Hyun Choi, Bo Won Kim, Sang Hee Kim   +3 more
doaj   +1 more source

Drug-Coated Balloon vs. Drug-Eluting Stent in Acute Myocardial Infarction: A Systematic Review and Updated Meta-Analysis

Anatolian Journal of Cardiology, 2023
Background: This study aimed to systematically review the evidence of drug-coated balloon used in the treatment of acute myocardial infarction and compared with using drug-eluting stent in terms of clinical and angiographic outcomes for a relatively long
Zhen Fang, Jun Ji, Shenghu He, Ning Liu, Bing Xu   +4 more
doaj   +1 more source

Drug-Coated Balloons for Restenosis Prophylaxis [PDF]

RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren, 2013
Drug-coated balloons for restenosis prophylaxis provide a high local drug concentration with minimal or no systemic adverse effects. Their development was both delayed and facilitated by the introduction of drug-eluting stents: delayed because sustained release kinetics from stent platforms seemed to be essential and facilitated because prior ...
U, Speck, B, Scheller, B, Hamm
openaire   +2 more sources

A novel paclitaxel coated balloon with increased drug transfer for treatment of complex vascular lesions.

PLoS ONE, 2021
BackgroundDrug coated balloons (DCB) with paclitaxel (Ptx) dose of 2-3.5 μg/mm2 balloon surface inhibit restenosis with different effectiveness and duration of success. A clinical dose finding study is not known for any of the currently marketed products.
Ole Gemeinhardt, Beatrix Schnorr, Ulrich Speck, Bruno Scheller   +3 more
doaj   +2 more sources